| 2026-08-06 | 10-Q | 10.3 | Lease Termination Agreement, by and between the Registrant and MIT 130 Brookline Leasehold LLC, dated as of April 1, 2026. (1) |
|---|
| 2026-05-11 | 10-Q | 10.2 | Fourth Amended and Restated Corporate Bonus Plan, effective April 15, 2026. (1) |
|---|
| 2026-05-11 | 10-Q | 10.1 | Eighth Amended and Restated Non-Employee Director Compensation Policy, effective April 15, 2026. (1) |
|---|
| 2026-02-26 | 10-K | 10.29 | Lease Agreement by and between the Registrant and Are-Winter Street Property, LLC, dated as of February 22, 2022 (11) |
|---|
| 2026-02-26 | 10-K | 10.25 | Second Amended and Restated Retirement Policy for Equity Awards, effective December 27, 2025 |
|---|
| 2025-08-07 | 10-Q | 10.6 | Form of Employee Restricted Stock Unit Award Agreement under 2025 Equity Incentive Plan. (1) |
|---|
| 2025-08-07 | 10-Q | 10.5 | Form of Employee Non-Qualified Stock Option Agreement under 2025 Equity Incentive Plan. (1) |
|---|
| 2025-08-07 | 10-Q | 10.4 | Form of Employee Incentive Stock Option Agreement under 2025 Equity Incentive Plan. (1) |
|---|
| 2025-08-07 | 10-Q | 10.3 | Third Amended and Restated Corporate Bonus Plan, effective June 25, 2025. (1) |
|---|
| 2025-08-07 | 10-Q | 10.2 | Amendment to Lease Agreement by and between the Registrant and ARE-Tech Square, LLC, dated as of July 2, 2025. (1) |
|---|
| 2025-02-27 | 10-K | 10.32 | Second Amendment to Lease Agreement by and between the Registrant and ARE-Winter Street Property, LLC, dated as of February 18, 2025 |
|---|
| 2025-02-27 | 10-K | 10.31 | Lease Agreement by and between the Registrant and ARE-Tech Square, LLC, dated as of February 18, 2025 |
|---|
| 2024-08-08 | 10-Q | 10.4 | Form of Employment Agreement for Executive Officers. (1) |
|---|
| 2024-08-08 | 10-Q | 10.1 | Seventh Amended and Restated Non-Employee Director Compensation Policy. (1) |
|---|
| 2024-06-26 | 8-K | 10.2 | Intellia Therapeutics, Inc. 2024 Inducement Plan and forms of award agreements thereunder |
|---|
| 2024-06-26 | 8-K | 10.1 | Employment Agreement between Intellia Therapeutics, Inc. and Edward Dulac |
|---|
| 2024-05-09 | 10-Q | 10.1 | Sixth Amended and Restated Non-Employee Director Compensation Policy. (1) |
|---|
| 2024-02-22 | 10-K | 10.23 | Second Amended and Restated Corporate Bonus Plan, effective November 30, 2023 |
|---|
| 2023-11-09 | 10-Q | 10.2 | Third Amendment to License and Collaboration Agreement by and between Registrant and Regeneron Pharmaceuticals, Inc., dated September 29, 2023. (1) |
|---|
| 2023-11-09 | 10-Q | 10.1 | Letter Agreement (Second Amendment) to License and Collaboration Agreement by and between Registrant and Regeneron Pharmaceuticals, Inc., dated November 22, 2022. (1) |
|---|
| 2023-08-03 | 10-Q | 10.1 | Amendment to Lease Agreement by and between the Registrant and Are-Winter Street Property, LLC, dated as of June 20, 2023. (1) |
|---|
| 2023-02-23 | 10-K | 10.30 | Amended and Restated Retirement Policy for Equity Awards, effective December 6, 2022 |
|---|
| 2022-08-04 | 10-Q | 10.2 | Amended and Restated Corporate Bonus Plan (1) |
|---|
| 2022-08-04 | 10-Q | 10.1 | Retirement Policy for Equity Awards (1) |
|---|
| 2022-05-05 | 10-Q | 10.4 | License and Collaboration Agreement dated as of April 11, 2016, by and between the Registrant and Regeneron Pharmaceuticals, Inc. (2) |
|---|
| 2022-05-05 | 10-Q | 10.3 | Fifth Amended and Restated Non-Employee Director Compensation Policy. (2) |
|---|
| 2022-02-24 | 10-K | 10.29 | Lease Agreement by and between the Registrant and Are-Winter Street Property, LLC, dated as of February 22, 2022 |
|---|
| 2022-02-24 | 10-K | 10.28 | Agreement and Plan of Merger, by and among Intellia Therapeutics, Inc., Rewrite Therapeutics, Inc., RW Acquisition Corp., and Shareholder Representative Services, LLC, as securityholder representative, dated as of February 2, 2022 |
|---|
| 2022-02-24 | 10-K | 10.16 | Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement dated December 15, 2016 by and between the Registrant, CRISPR Therapeutics AG, The Regents of the University of California, University of Vienna, ERS Genomics Ltd., TRACR Hematology Ltd., Caribou Biosciences, Inc., and Dr. Emmanuelle Charpentier |
|---|
| 2021-06-17 | 8-K | 10.1 | Amendment #3 to License and Collaborative Research Agreement, dated as of June 14, 2021, by and between Novartis and Intellia |
|---|
| 2021-05-06 | 10-Q | 10.3 | Fourth Amended and Restated Non-Employee Director Compensation Policy (1) |
|---|
| 2021-05-06 | 10-Q | 10.2 | License and Collaborative Research Agreement dated as of December 18, 2014 by and between Registrant and Novartis Institutes for BioMedical Research, Inc. (1) |
|---|
| 2021-05-06 | 10-Q | 10.1 | License Agreement dated as of July 16, 2014 by and between Registrant (as successor in interest of Intellia Therapeutics, LLC) and Caribou Biosciences, Inc. (1) |
|---|
| 2021-02-26 | 10-K | 10.21 | Third Amended and Restated Non-Employee Director Compensation Policy |
|---|
| 2020-08-06 | 10-Q | 10.3 | Corporate Bonus Plan, effective April 3, 2020. (2) |
|---|
| 2020-06-01 | 8-K | 10.2 | Stock Purchase Agreement, dated May 30, 2020, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. |
|---|
| 2020-06-01 | 8-K | 10.1 | Amendment No. 1, dated May 30, 2020, to the License and Collaboration Agreement, dated April 11, 2016, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. |
|---|
| 2020-05-07 | 10-Q | 10.2 | Second Amendment to Lease, dated as of March 12, 2020, by and between the Company and MIT 130 Brookline Leasehold LLC. (1) |
|---|
| 2020-05-07 | 10-Q | 10.1 | Lease, dated as of March 12, 2020, by and between the Company and 281-295 Albany Street Leasehold LLC. (1) |
|---|
| 2020-02-27 | 10-K | 10.21 | Second Amended and Restated Non-Employee Director Compensation Policy |
|---|
| 2019-05-02 | 10-Q | 10.1 | First Amendment to Lease, dated as of April 5, 2019, by and between the Company and MIT 130 Brookline Leasehold LLC. (1) |
|---|
| 2019-05-02 | 10-Q/A | 10.1 | Letter Agreement, dated as of July 20, 2018, by and between the Company and Regeneron Pharmaceuticals, Inc. and the corresponding Form of Co-Development and Co-Promotion Agreement, by and between the Company and Regeneron Pharmaceuticals, Inc. (1) |
|---|
| 2019-02-27 | 10-K | 10.19 | Agreement and Amendment to License and Collaborative Research Agreement, dated as of December 3, 2018, by and between Novartis and the Company (10) |
|---|
| 2018-10-31 | 10-Q | 10.1 | Letter Agreement, dated as of July 20, 2018, by and between the Company and Regeneron Pharmaceuticals, Inc. and the corresponding Form of Co-Development and Co-Promotion Agreement, by and between the Company and Regeneron Pharmaceuticals, Inc. (1) |
|---|
| 2018-04-17 | 8-K | 10.1 | Form of Amended and Restated Employment Agreement |
|---|
| 2016-12-16 | 8-K | 10.1 | Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement dated December 15, 2016 by and between the Registrant, CRISPR Therapeutics AG, The Regents of the University of California, University of Vienna, ERS Genomics Ltd., TRACR Hematology Ltd., Caribou Biosciences, Inc., and Dr. Emmanuelle Charpentier |
|---|